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ABSTRACT
Objective: Metabolic syndrome, a cluster of cardiometabolic
risk factors, is associated with a twofold increased risk of
developing artherosclerotic cardiovascular disease and a ﬁve-
fold increased risk of developing diabetes, compared to
individuals without metabolic syndrome. For a typical
employer-sponsored health beneﬁts program and population,
we estimate the medical cost generated by employees and
covered dependents with and without metabolic syndrome,
with an emphasis on costs associated with cardiovascular
events.
Methods: National Health and Nutrition Examination Sur-
vey (NHANES) 1999 to 2000 and NHANES 2001 to 2002
data sets were used to identify the prevalence of metabolic
syndrome (based on National Cholesterol Education Pro-
gram Adult Treatment Panel III [NCEP ATP III] criteria) in
the 20- to 69-year-old age group and calculate the Framing-
ham risk score for coronary artery disease (CAD) and
stroke events. We created a 3-year event model and per-
formed Monte Carlo simulation to produce event occur-
rence for each individual. Results were tabulated for people
with and without metabolic syndrome and adjusted for a
typical working-age demographic mix. MedStat Markets-
can™ was used to develop costs of CAD and stroke events
and the incremental contributing cost of metabolic syn-
drome. We applied these costs to working-age cohorts with
and without metabolic syndrome to calculate the cost dif-
ference between cohorts.
Results: Working-age individuals with metabolic syndrome
had signiﬁcantly higher medical costs compared to those
without metabolic syndrome: $626 per member per month
(PMPM) for those with metabolic syndrome compared to
$367 PMPM for those without metabolic syndrome. Of the
$259 excess medical cost for individuals with metabolic syn-
drome, $46 is because of additional cardiovascular events
and $213 is because of the expense of higher prevalence
of comorbidities, particularly cardiovascular disease and
diabetes.
Conclusions: These ﬁndings show that most cardiovascular
cost and risk borne by employers is concentrated in the one-
third of the working-age population with metabolic syn-
drome. Employers need resources and approaches for treat-
ing and managing metabolic syndrome that combine health,
wellness, and medical management programs to enhance
screening, identiﬁcation, and treatment of the risk-factor
components of metabolic syndrome.
Keywords: CAD and stroke events, cardiometabolic risk fac-
tors, employer medical cost, Framingham risking, metabolic
syndrome, NCEP, NHANES, PMPM incremental costs.
Introduction
Metabolic syndrome has recently received increased
attention as a signiﬁcant health concern and cost driver
for employers sponsoring medical beneﬁt programs.
About 23% of the US adult population has metabolic
syndrome with much higher prevalence in the work-
ing-age population [1]. Studies show that metabolic
syndrome brings an approximate twofold increase in
relative risk for atherosclerotic cardiovascular disease
(ASCVD), and an approximate ﬁvefold increase in risk
for developing diabetes compared to people without
the syndrome [2]. Medco Health Solutions, Inc., ana-
lyzed claims from approximately two million adult
patients aged 20 and older and found that individuals
taking medications for at least three of the risk factors
associated with metabolic syndrome had an annual
drug spend more than four times that of all other
patients [3].
Deﬁnition
Metabolic syndrome is deﬁned as a cluster of risk
factors of metabolic origin—metabolic risk factors—
that appear to directly promote the development of
ASCVD and increase risk for developing type 2 diabe-
tes mellitus [4]. The National Cholesterol Education
Program, Adult Treatment Panel III (NCEP ATP III)
identiﬁes components of the metabolic syndrome that
relate to cardiovascular disease, including abdominal
obesity, atherogenic dyslipidemia, raised blood pres-
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sure, insulin resistance, proinﬂammatory state, and
prothrombic state [5].
There have been several criteria sets proposed for
the clinical diagnosis of metabolic syndrome over the
past 10 years. The most widely accepted criteria and
that proposed by the American Heart Association
(AHA) and National Heart, Lung and Blood Institute
(NHLBI), is that of NCEP ATP III. This criteria set
(with minor modiﬁcations by AHA/NHLBI) identiﬁes
an individual as having metabolic syndrome if he or
she has at least three of the ﬁve following risk factors
[4].
1. Elevated waist circumference.
• ≥102 cm (≥40 inches) in men;
• ≥88 cm (≥35 inches) in women.
2. Elevated triglycerides.
• ≥150 mg/dL (1.7 mmol/L); or
• On drug treatment for elevated triglycerides.
3. Reduced HDL-C.
• <40 mg/dL (1.03 mmol/L) in men;
• <50 mg/dL (1.3 mmol/L) in women; or
• On drug treatment for reduced HDL-C.
4. Elevated blood pressure.
• ≥130 mmHg systolic blood pressure; or
• ≥85 mmHg diastolic blood pressure; or
• On antihypertensive drug treatment in a
patient with a history of hypertension.
5. Elevated fasting glucose.
• ≥100 mg/dL; or
• On drug treatment for elevated glucose.
Etiology and Treatment
Although the exact cause of metabolic syndrome is not
clear, there seem to be three potential causes: Abdom-
inal obesity and disorders of adipose tissue; insulin
resistance; and a constellation of independent factors.
Other factors that have been cited are aging, proin-
ﬂammatory state, and hormonal changes [6]. The risk
for ASCVD depends on which metabolic risk factors
are present as well as the presence of other risk factors.
The most important metabolic syndrome risk factors
are abdominal obesity and insulin resistance while
other associated risk factors are physical inactivity,
aging, and hormonal imbalance [6].
First-line therapy recommended for metabolic syn-
drome is lifestyle interventions to reduce the metabolic
syndrome risk factors. The major lifestyle interven-
tions include weight loss in overweight or obese
patients, increased physical activity, and modiﬁcation
of an atherogenic (high-fat) diet. Drug therapy is rec-
ommended for the treatment of risk factors (dyslipi-
demia, elevated blood pressure, elevated glucose) [4].
We used epidemiological and medical cost data to
estimate the medical cost generated by employees and
covered dependents with and without metabolic syn-
drome, with an emphasis on costs associated with car-
diovascular events.
Methods
We mapped the NCEP ATP III modiﬁed criteria for
metabolic syndrome to the NHANES 1999–2000 and
NHANES 2001–2002 (NHANES 1999–2002) survey
data using the NHANES survey ﬁelds listed in Table 1.
Using the Framingham stroke and coronary artery
disease (CAD) risking methodology [7–9], we calcu-
lated the annual risks of having a stroke or CAD event
and death for NHANES 1999–2002 individuals
with and without metabolic syndrome. We used the
Table 1 Mapping metabolic syndrome risk factors to NHANES survey ﬁelds
Metabolic syndrome risk factors NHANES survey ﬁelds
Waist circumference BMXWAIST
Triglycerides LBXTR, or
On drug treatment for elevated triglycerides:
Niacin 42700 (NH code in drug ﬁle)
Fenoﬁbrate 24400 (NH code in drug ﬁle)
Gemﬁbrozil 27000 (NH code in drug ﬁle)
HDL-C LBDHDL, or
On drug treatment for reduced HDL:
Niacin 42700 (NH code in drug ﬁle)
Fenoﬁbrate 24400 (NH code in drug ﬁle)
Gemﬁbrozil 27000 (NH code in drug ﬁle)
Blood pressure:
systolic BPXSAR
diastolic BPXDAR, or
On antihypertensive drug treatment in a patient with a history of hypertension:
Drug ﬁle 0506 (antihypertensives)
BPQ050A: Now taking prescribed medicine for hypertension
Fasting glucose LBXGLU, or
On drug treatment for elevated glucose:
DIQ050 Are you now taking insulin
DIQ070 Are you taking diabetes pills
NHANES, National Health and Nutrition Survey; HDL, high density lipoprotein.
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NHANES survey ﬁelds from Table 2 to identify those
with the Framingham risk factors.
We modeled the number of strokes, CAD events,
and deaths that would occur over 3 years for individ-
uals with and without metabolic syndrome. In accord-
ance with the Framingham risk scoring methods we
used, we assigned no CAD primary event risk to indi-
viduals under 30, no CAD secondary event risk to
individuals under 35 and no stroke event risk to those
under 55. We developed mortality rates for poststroke
and post-CAD from rates reported in the literature
[10]. We applied these rates to each year following a
stroke or CAD event. Standard, life insurance mortal-
ity rates were used to account for mortality due to
other causes. We applied the portions of metabolic
syndrome lives by quinquennial age groups and sex
to a standard employee adult population (10,000
employees and their spouses) covered through a typical
large employer. The latter was from the Milliman 2005
Health Cost Guidelines.
We modeled medical costs and events for a 3-year
period. The medical costs included all paid claims (net
of coinsurance) for commercially insured populations
including physician, inpatient, outpatient, and phar-
macy claims. The results present the average annual
costs and events over the 3-year period. We used a 3-
year period as this reﬂects a compromise between a
long-term study and the short-term horizon of many
employee beneﬁt managers. To produce our cost esti-
mates, we applied annual historical per-person medical
claim costs identiﬁed in Medstat Marketscan™ claims
data. These annual per-person costs were developed
separately by gender by 5-year age bands for each
event state and for nonevent years.
We identiﬁed individuals with claims for CAD and
stroke events using a combination of International
Classiﬁcation of Diseases (ICD) 9th edition and cur-
rent procedural terminology (CPT) code logic. We
used these event costs (costs during the year of an
event) and costs incurred in years 2 and 3 after an
event, for individuals having a CAD or stoke event,
whether or not they had metabolic syndrome. We did
not apply a distinct medical cost to events that resulted
in death.
For those with metabolic syndrome, we developed
“no event year costs” using a regression model that
captured the costs of people with diabetes, previous
CAD, and hypertension. We applied the NHANES dis-
tribution of diabetes, CAD, and hypertension for peo-
ple with metabolic syndrome and assigned costs to
each of these conditions to arrive at an average of $544
PMPM for those with metabolic syndrome. For those
without metabolic syndrome we developed “no event
year costs” in a similar way to arrive at an average of
$273 PMPM. We used the “no event year costs” for
those not having an event for each of the 3 years of our
modeling as well as for years prior to an event for
those having an event in year 2 or 3.
The costs of people during the year of an event
include a small number of individuals with multiple
events. In our modeling, we adjusted event rates to
avoid double counting individuals who may have more
than one type of event in 1 year. Our model assumed
that an individual could have, at most, one type of car-
diovascular event (stroke, myocardial infarction [MI]
without revascularization, MI with revascularization,
or revascularization without MI) over the 3-year
model period. We created a 3-year event model by pro-
ducing Framingham risks for each working-age indi-
vidual having adequate NHANES survey data. Our
Monte Carlo simulation used 5000 iterations for each
individual. We applied weights speciﬁed in NHANES
and adjusted the age–sex distribution for our standard
employer group demographics.
Table 2 Mapping Framingham risk factors to NHANES survey ﬁelds
Framingham risk factor NHANES survey ﬁeld
Diabetes any one DIQ050 Are you now taking insulin
DIQ070 Are you taking diabetes pills
Drug ﬁle 1036 (blood glucose regulators)
DIQ010 Have you ever been told by a doctor that you have diabetes or sugar diabetes
Cardiovascular disease any one MCQ160C Doctor ever told you had CAD
MCQ160D Doctor ever told you had angina
MCQ160E Doctor ever told you had a heart attack
Drug ﬁle 0503 antianginals
Drug ﬁle 0508 coronary vasodilators
MCQ160B Doctor told you had CHF
BPXSAR—Systolic BP average reported to examinee >160, or
BPXDAR—Diastolic BP average reported to examinee diastolic
BP > 90
Drug ﬁle 0506 (antihypertensives)
BPQ050A Now taking prescribed medicine for hypertension
MCQ160F—Has a doctor ever told you that you had a stroke
Cigarettes SMQ040—Do you now smoke cigarettes?
HDL LBDHDL
Total cholesterol LBXTC
BP, blood pressure; CAD, coronary artery disease; CHF, congestive heart failure.
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Results
Prevalence
We identiﬁed a metabolic syndrome prevalence rate of
33% for a working-age population (20- to 69-year-
olds). Figure 1 shows prevalence rates increasing with
age, and prevalence rate for women surpassing men
after age 60. The average age of those working-age
people with metabolic syndrome in NHANES was 46
and the average age of those without metabolic syn-
drome was 40.
The majority of individuals identiﬁed with meta-
bolic syndrome had the minimum three out of ﬁve risk
factors (55%) while 32% had four risk factors and
13% had all ﬁve risk factors. The most common risk
factors found in individuals with metabolic syndrome
were abdominal obesity and dyslipidemia. This sup-
ports the AHA/NHBLI statement that the major life-
style interventions for metabolic syndrome include
weight loss, increased physical activity, and modiﬁca-
tion of an atherogenic (high-fat) diet.
The prevalence of diabetes, CAD, and hypertension
are signiﬁcantly higher in the metabolic syndrome
cohort, particularly because the metabolic syndrome
criteria includes active treatment for diabetes and
hypertension as well as the presence of elevated glu-
cose and blood pressure. Yet 70% of individuals with
metabolic syndrome have not been diagnosed as
having CAD or diabetes and therefore may not be
receiving medical care to combat their higher risk of
developing ASCVD and diabetes.
Risk for CAD and Stroke Events
Applying the Framingham risking methodology [7–9]
to the NHANES population, we calculated each indi-
vidual’s probability of CAD (heart attack, coronary
revascularization, and/or angina) and stroke events.
Those with metabolic syndrome have approximately
2.5 times the risk of a CAD event and double the risk
of a stroke event over a 3-year period compared to
those without metabolic syndrome. Figures 2 and 3
illustrate these ﬁndings.
The decline in CAD risk in women after age 60 in
Figure 2 appears to be associated with a signiﬁcant
decline in smoking and moderate decline in diabetes in
this age group. We tested whether smoking prevalence
is a driver for the difference in CAD and stroke risk
between those with and without metabolic syndrome
and found the difference in smoking rates to be a
minor factor, with reported smoking prevalence rates
of 25% for those with metabolic syndrome and 22%
for those without metabolic syndrome.
Figure 4 illustrates the number of events that would
occur over a 3-year period for an employer with
10,000 employees (plus 4721 spouses). People with
metabolic syndrome will generate almost twice as
Figure 1 Prevalence of metabolic syndrome in a working-age population.
Sources: NHANES 1999–2002, Milliman HCG 2005 Standard
Demographics.
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Figure 2 Three-year risk of CAD events in working-age population with
and without metabolic syndrome. Source: NHANES 1999–2002, Milliman
HCG 2005 Standard Demographics. Framingham risking methodology:
Wilson PW, D’Agostino RB, Levy D, et al. [8]. (For primary prevention
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Figure 3 Three-year risk of stroke in working-age population with and
without metabolic syndrome. Source: NHANES 1999–2002, Milliman
HCG 2005 Standard Demographics, D’Agostino RB, Wolf PA, Belanger AJ,
Kannel WB [7]. This risking is only applied to individuals ≥55 as indicated
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many deaths from CAD events and strokes over 3
years. We have not attempted to assign life insurance
or replacement costs for these deaths.
Contributing Costs
Costs during the year of a stroke or CAD event are pre-
sented in Figure 5. The event costs reﬂect all the medical
costs incurred by a patient during the year of an event.
Although, on average, costs for these people decrease in
subsequent years, they are still relatively high for several
years following these events and we used these subse-
quent year costs in our modeling. We also developed
“no event costs” separately for individuals with and
without metabolic syndrome to account for costs in
years prior to an event and for those experiencing no
events. All costs are projected to 2006 dollars.
Figure 6 summarizes the impact of several cost-
increasing characteristics of people with metabolic
syndrome. These people are higher cost because they
have
Figure 4 Three-year projection of CAD
and stroke events for 10,000 employees plus
spouses. Source: NHANES 1999–2002, Milli-
man HCG 2005 Standard Demographics,
Framingham Risking Study.
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• More CAD and stroke events;
• Higher costs in the years after the events;
• When they do not have events, people with met-
abolic syndrome incur more costs related to their
higher prevalence of hypertension, diabetes, and
CAD.
Figure 6 distinguishes the cost impact of metabolic
syndrome from the impact of age for the average per-
son with metabolic syndrome. We show the projected
PMPM costs for people with metabolic syndrome, and
the costs of people with the same age–sex mix, but
without metabolic syndrome. Our modeling shows
that people with metabolic syndrome cost $259
PMPM more than people with the same age–sex mix
but without metabolic syndrome. About $46 PMPM
of the excess is because of events and $213 PMPM is
because of the nonevent costs, mostly associated with
CAD and diabetes.
Discussion/Potential for Progress
This report indicates that people with metabolic syn-
drome are expensive for employee health beneﬁts pro-
grams. Although costs to employers associated with
metabolic syndrome are not reported in the literature,
costs attributable to obesity are reported to be 11.6%
percent of private insurance spending in 2002. A
higher prevalence of diabetes, hypertension, and
hyperlipidemia in the obese population is considered a
major driver of the increased costs; these are compo-
nents of metabolic syndrome [11]. It is not clear if
employers are aware of this risk.
Similarly, it appears as though people with meta-
bolic syndrome are unaware of their risk. Our ﬁndings
suggest that, although most cardiovascular cost and
risk borne by employers is concentrated in the one-
third of working-age people with metabolic syndrome,
the majority of those with metabolic syndrome receive
no treatment for their increased cardiovascular risk.
Of those with metabolic syndrome, 71% do not have
diagnosed CAD or diabetes and may not be seeking
medical care. A high portion of people with risk fac-
tors for cardiovascular disease are undiagnosed, which
poses a signiﬁcant challenge for both the public health
arena and for employers. Table 3 shows some readily
available ﬁgures of the portion of people with cardio-
vascular risk factors who have not been diagnosed.
While these ﬁgures do not come from a typical
employee population, the under-diagnosis is dramatic.
Most of the undiagnosed people will appear relatively
healthy but some are at very high risk.
The need for identiﬁcation and risk-factor treat-
ment of those with metabolic syndrome is shared by
both employers and employees. On-site services such
as health fairs, clinics, and consumer-friendly testing
devices can help identify people at risk; and because
they are on-site, they bring a strong message from the
employer. Wellness vendors offer a wide variety of pro-
grams and techniques to promote screening. Health
risk assessment tools can and should be modiﬁed to
include metabolic syndrome risk factors. A challenge
with all of these tools is reaching high-risk people who
do not want to participate. Some employers use ﬁnan-
cial incentives or penalties to promote participation.
Despite the advantages of on-site identiﬁcation, we
believe physician ofﬁce visits will continue to be a main
source of identiﬁcation of risk factors. Physicians often
improve risk factor screening efforts when payers
measure and provide feedback on individual physician
screening compliance. Health Plan Employer Data and
Information Set (HEDIS) measures provide examples
of how measurement can improve performance [12].
Initiatives to encourage providers to code for metabolic
syndrome should be investigated with health plans.
Although an ICD-9 code (277.7) was established for
metabolic syndrome in 2002, our analysis found only
0.1% of a working-age population to have claims
coded with this ICD-9. This contrasts sharply with the
33% we estimate as having metabolic syndrome.
After identiﬁcation, the main treatment for meta-
bolic syndrome components other than lifestyle
changes is medication. While medical evidence proves
that changes in diet and exercise will dramatically
help manage metabolic syndrome risk factors, many
patients will require drug therapy. Drug therapy com-
pliance reduces events among people with dyslipi-
demia, hypertension, and diabetes. Pharmacy beneﬁt
managers (PBMs) and disease management companies
use data analysis to identify patients who are not
compliant with prescriptions and have programs to
encourage compliance. Innovative beneﬁt design pro-
grams adjust copays to promote compliance for critical
need/value-based medications, taking advantage of the
well-known fact that lower copays increase utilization
[13]. Low-cost generic drugs are increasingly available
for many of the cardio metabolic risk factors. This
gives employers a tool to help manage costs while
improving outcomes.
The data suggest that a focus on diabetes and pre-
diabetes would be especially worthwhile. For diabet-
ics, intensive blood sugar monitoring, regular retinal
and foot exams, lipid testing, physical activity, and diet
are associated with better outcomes. Medication com-
Table 3 Percent of people unaware/undiagnosed with cardio-
vascular risk factors. National estimates based on survey data
Condition
Percent of people with condition
that are unaware/undiagnosed
Hypertension (adults) 36.6 [17]
Diabetes (adults) 29.0 [18]
Prediabetes (ages 40–74) Over 50 [16]
Hyperlipidemia* (workforce) 41.0 [19]
*LDL cholesterol of 130 mg/dL or higher.
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pliance and hemoglobin A1c levels are key metrics.
Prediabetics may need medication therapy, but exer-
cise and weight control will produce dramatically bet-
ter outcomes. Most of these inputs and outputs can be
measured and compared to established benchmarks.
Successful treatment of obesity through weight-loss
programs has been frustrating, even though the obesity
epidemic is widely recognized, as are the negative con-
sequences of obesity. Employers may be interested in
the emerging novel therapies that may have more suc-
cess. In the meantime, employer coalitions have begun
addressing obesity and many resources are available
[14]. Some lifestyle management vendors are using
personalized web-based systems to promote wellness
[15] while most disease management companies con-
centrate their efforts on telephonic and mail contact.
Visible, personal executive commitment to diet, exer-
cise, smoking cessation, and other wellness programs
will motivate some employees. The authors are opti-
mistic that the attention being paid to obesity will
produce scientiﬁcally validated weight-loss, behavio-
ral, and medical programs.
Most employers will ﬁnd it easiest to take action
through third parties such as
• The health beneﬁts insurer, health maintenance
organization (HMO) or administrator;
• Disease management vendors;
• Behavioral carve-out companies, employee assist-
ance plans, or special wellness programs.
For any actions or treatments—on-site, medication,
or weight-loss programs—measuring results is key.
Employers have leverage in negotiations with insurers,
administrators, PBMs, and disease management com-
panies to produce meaningful metrics and year-to-year
improvements. Chronic medication compliance should
mean the portion of patients who reﬁll particular med-
ications for the entire year—not, for example, the
portion of diabetics who have ﬁlled at least one
prescription for a statin during the year.
The extra costs of people with metabolic syndrome
presented provide a rough estimate for a higher pre-
mium contribution for these people. Charging people
higher premiums based on their risk is well-established
for life insurance, but is controversial in employer-
sponsored programs. Some jurisdictions may regulate
how this can be done for health beneﬁts, so an
employer should consult a beneﬁts attorney.
Given the wide variety of tools and approaches,
employers should evaluate whether current in-house or
outsourced programs are identifying and managing
metabolic syndrome risk factors and identify enhance-
ments that can be made to current programs as well as
explore the need for new programs.
We would like to note that our conclusions need to
be viewed in the context of the particular assumptions
and conditions of the underlying data sources. In par-
ticular, others applying other deﬁnitions of “metabolic
syndrome” would produce somewhat different results,
and the Framingham risking methodologies we used
are subject to revisions that may change their forecasts.
Each of the data sources we used also has its own lim-
itations. For example, NHANES data include survey
information that may be inaccurate, and the coding of
medical claims data reﬂects business practices rather
than clinical trial standards. The application of our
results to any particular population should consider
adjustments to reﬂect the impact of demographic, uti-
lization, health status, or reimbursement differences
from our national representative ﬁgures.
Source of ﬁnancial support: This report was commissioned
by sanoﬁ-aventis, Inc. 
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